ICON (ICLR) vs Incyte (INCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Incyte (INCY) has outperformed ICON (ICLR) over the past year, gaining 30.1% versus a loss of 12.1%. Over five years, INCY leads with a +73.0% price change compared with -40.3% for ICLR. Incyte is the larger company by market cap ($22.85 billion vs $12.69 billion), about 1.8 times the size.
On valuation, Incyte trades at a lower forward P/E (12.9x vs 13.9x for ICON). Incyte converts more of its revenue into profit, with a net margin of 25.0% versus 2.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICLR | INCY |
|---|---|---|
| Share price | $164.50 | $112.75 |
| Market cap | $12.69B | $22.85B |
| 1-day change | +0.26% | -0.61% |
| YTD return | -9.95% | +14.85% |
| 1-year return | -12.09% | +30.14% |
| 5-year return | -40.34% | +73.03% |
| P/E ratio (TTM) | 173.16 | 14.36 |
| Forward P/E | 13.92 | 12.89 |
| EPS (TTM) | $0.95 | $7.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.25B | $5.14B |
| Revenue growth (YoY) | +0.76% | +21.22% |
| Net income (latest FY) | $229.34M | $1.29B |
| Gross margin | 26.37% | 92.76% |
| Operating margin | 5.37% | 29.46% |
| Net margin | 2.78% | 25.03% |
| 52-week high | $203.91 | $132.60 |
| 52-week low | $66.57 | $82.82 |
| Distance from 52-week high | -19.33% | -14.97% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +12.10% | +14.34% |
| Average volume | 814.74K | 1.62M |
| Shares outstanding | 77.15M | 202.70M |
| Employees | 40,200 | 2,844 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INCY has outperformed ICLR by 42.2 percentage points over the past year.
- ICON trades at a higher earnings multiple (173.2x vs 14.4x trailing P/E).
- Incyte is more profitable, keeping 25.0 cents of every revenue dollar as net income versus 2.8 cents for ICON.
- Incyte grew revenue faster in its latest fiscal year (+21.22% vs +0.76%).
About ICON
ICLR stock →ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 40,200 employees
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
ICLR vs INCY FAQ
Which is bigger, ICON or Incyte?
Incyte (INCY) is larger, with a market capitalization of $22.85B compared with $12.69B for ICON (ICLR).
Which stock has performed better over the past year, ICLR or INCY?
INCY returned +30.14% over the past 12 months, compared with -12.09% for ICLR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ICLR or INCY?
INCY has the lower trailing P/E at 14.4, versus 173.2 for ICLR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are ICON and Incyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.